These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2182781)

  • 1. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
    MacMahon DG; Sachdev D; Boddie HG; Ellis CJ; Kendal BR; Blackburn NA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
    Clin Neuropharmacol; 1989 Dec; 12(6):498-505. PubMed ID: 2691069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Madopar HBS in Parkinson patients with nocturnal akinesia.
    Jansen EN; Meerwaldt JD
    Clin Neurol Neurosurg; 1988; 90(1):35-9. PubMed ID: 3359732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Madopar HBS in nocturnal symptoms of Parkinson's disease.
    Jansen EN; Meerwaldtt JD
    Adv Neurol; 1990; 53():527-31. PubMed ID: 2239493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance.
    Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
    Acta Neurol Scand; 1988 May; 77(5):422-5. PubMed ID: 3046226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.
    Graham JS; Henderson JM; Morris JG; Yiannikas C
    Aust N Z J Med; 1991 Feb; 21(1):11-5. PubMed ID: 2036070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
    Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
    Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
    Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
    Dupont E; Andersen A; Boas J; Boisen E; Borgmann R; Helgetveit AC; Kjaer MO; Kristensen TN; Mikkelsen B; Pakkenberg H; Presthus J; Stien R; Worm-Petersen J; Buch D
    Acta Neurol Scand; 1996 Jan; 93(1):14-20. PubMed ID: 8825266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
    Jansen EN; Meerwaldt JD; Heersema T; van Manen J; Speelman JD
    Eur Neurol; 1987; 27 Suppl 1():88-92. PubMed ID: 3322841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
    Quinn NP; Marion MH; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():105-13. PubMed ID: 3322834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
    Chouza C; Aljanati R; Caamaño JL; De Medina O; Scaramelli A; Buzó R; Plachín V; Fernandez A; Romero S
    Adv Neurol; 1990; 53():519-26. PubMed ID: 2122654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
    Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease.
    Lees AJ
    Adv Neurol; 1990; 53():475-82. PubMed ID: 2239487
    [No Abstract]   [Full Text] [Related]  

  • 19. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
    Rinne UK; Birket-Smith E; Dupont E; Hansen E; Hyyppä M; Marttila R; Mikkelsen B; Pakkenberg H; Presthus J
    J Neurol; 1975 Dec; 211(1):1-9. PubMed ID: 56427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open clinical study of Madopar HBS.
    Ludin HP
    Eur Neurol; 1987; 27 Suppl 1():73-5. PubMed ID: 3322838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.